Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 39 Leukemia, Myeloid, Acute 35 Myelodysplastic Syndromes 33 Multiple Myeloma 30 Lymphoma, Non-Hodgkin 29 Hodgkin Disease 28 Graft vs Host Disease 26 Leukemia, Lymphocytic, Chronic, B-Cell 25 Lymphoma 24 Leukemia 24 Hematologic Neoplasms 20 Neoplasms 18 Lymphoma, Mantle-Cell 18 Sarcoma 17 Leukemia, Myelogenous, Chronic, BCR-ABL Positive 17 Breast Neoplasms 17 Tuberous Sclerosis 15 Myeloproliferative Disorders 15 Lymphoma, Large B-Cell, Diffuse 15 Lymphoma, Follicular 14 Burkitt Lymphoma 14 Waldenstrom Macroglobulinemia 13 Lymphoma, B-Cell, Marginal Zone 13 Recurrence 12 Neoplasm Metastasis 12 Carcinoma, Non-Small-Cell Lung 12 Prostatic Neoplasms 11 Primary Myelofibrosis 11 Melanoma 11 Leukemia, Myelomonocytic, Chronic 11

Interventions

perampanel 1 Sirolimus 1 Immunoglobulins, Intravenous 1 Diet, Ketogenic 1 Cannabidiol 1 Anticonvulsants 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Drug Resistant Epilepsy × Sirolimus × Clear all

NCT05534672 2023-08-08

RaRE-TS

Children's Memorial Health Institute, Poland

Phase 3 Recruiting

Drug Resistant Epilepsy, Epilepsy, Tuberous Sclerosis

Data powered by HemOnc (CC BY 4.0) Colophon ⚡